Evidence map›Paper›PMID 31232617›Full record

ReviewExpert opinion on pharmacotherapy2019

Current pharmacotherapy for the treatment of dyslipidemia associated with HIV infection.

Anna Gebhardt, Carl J Fichtenbaum

Open access · greenAbstract readReview
In one paragraph

Review in Expert opinion on pharmacotherapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 2 pooled it
2.6field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 2 syntheses or guidelines pooled it, 20 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Anna GebhardtDivision of Infectious Diseases, Department of Internal Medicine, University of Cincinnati College of Medicine , Cincinnati , OH , USA.
Carl J FichtenbaumDivision of Infectious Diseases, Department of Internal Medicine, University of Cincinnati College of Medicine , Cincinnati , OH , USA.ORCID https://orcid.org/0000-0002-6778-7253
University of Cincinnati Medical Center · US

Funding

Case Clinical Trials Unit: Administrative Supplement NOSI AI-20-031.UM1AI069501 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI George Yendewa · 2012 to 2026
$40.4M
Case AIDS Clinical Trials UnitU01AI069501 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI LEDERMAN, MICHAEL MARCEL · 2007 to 2011
$14.7M
NIAID NIH HHS U01 AI069501NIAID NIH HHS UM1 AI069501
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Anti-Retroviral AgentsDrug InteractionsDyslipidemiasEzetimibeHIV InfectionsHumansHydroxymethylglutaryl-CoA Reductase InhibitorsHypolipidemic AgentsNiacinRisk AssessmentAnti-Retroviral AgentsEzetimibeHydroxymethylglutaryl-CoA Reductase InhibitorsHypolipidemic AgentsNiacinDyslipidemiaHIVHMG-CoA reductase inhibitorsPCSK-9 inhibitorsstatins

Identifiers

PMID31232617
PMCPMC6756942
OpenAlexW2954083641

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.